Aim: This retrospective study was designed to analyze expression patterns of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu in Albanian patients with breast carcinoma to identify their relationships with tumor size, histological grade (HG), lymph node metastasis and relapse.
INTRODUCTION
Estrogen receptor (ER) and progesterone receptor (PR) expressions are the most important and useful predictive factors currently available. ER and PR are intracellular steroid hormone receptors which have received a great attention since 1986. Measurable amounts of ER and PR are found in about 50-85% of patients with breast cancer. Steroid receptor testing for ER and PR by immunohistochemistry is the established standard of care with almost 70-80% of the tumors in breast cancer being ER and/or PR positive (1) . The frequency of positivity and the level of ER and PR increase with age, reaching their highest levels in postmenopausal women (2) . Men have higher ER and PR expression as compared to female breast cancer patients without any association with histological prognostic markers (3) .
Factors that are known to be important in the prognosis of breast malignancies in individual patients include: size of the primary tumor, stage of the disease at diagnosis, hormonal receptor status, and number of lymph nodes involved with disease. A number of studies have shown the prognostic and predictive significance of ER and PR in breast cancer patients (1, (4) (5) (6) . Generally, the frequency of receptor positivity is inversely correlated with HER2/neu (7, 8) . Negative ER, PR have been found to be associated with higher tumour grade, larger tumour size, aggressive histopathological type, and recurrence (9, 10) .
Overexpression of the HER2/neu oncogene is also important event in breast cancer tumorigenesis. The HER2/neu receptor is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, which are considered to be important mediators of cell proliferation and differentiation (11) . It is activated in 20% to 30% of cases through amplification and overexpression of the oncogene. Overexpression of HER2/neu reflects an increased proliferative activity of the tumor. HER2/neu positivity has been reported to be a negative predictor of response to hormonal therapy, adjuvant radiotherapy, and adjuvant chemotherapy (12, 13) . The determination of correct HER2/neu tumor status is criti-cally important for guiding the therapy of patients with HER2/neu positive breast cancer treated with Trastuzumab (Herceptin) (14) .
The objective of this study was to determine the biological differences that exist between steroid hormone receptor and epidermal growth factor receptor-2 and their association with histological prognostic markers in female breast carcinoma in Albania.
MATERIALS AND METHODS
The association between breast tumor characteristics and expression of ER, PR¸ HER2/neu, patient's age, tumor size, lymph nodes status, and tumor grade were retrospectively evaluated in primary breast cancer patients diagnosed between January 2006 and December 2007 at "Nene Tereza" Oncologic Hospital in Tirana, treated till January 2010 -December 2011. The study population included 123 patients in the age group of 26-76 years. Among them 11 patient who had benign breast diseases and 2 male patients were excluded from the study. Only 110 histologically confirmed female breast cancer patients in different stages of the disease were selected for our study. Median follow-up for all of the patients analyzed is 48.4 month (range 36.2-64.4 months). All patient characteristics are listed in Table 1 .
Patients were grouped according to age ≤ 50 years and > 50 years. Age of the patient was taken as age rounded to the nearest figure in years at the time of biopsy/surgery of the tumor. Tumor size was classified as < 2 cm, 2-5 cm and > 5 cm and lymph nodes were grouped as 1-3, 4-9 and > 9 based on TNM staging for breast carcinoma.
Factors that are known to be important in the prognosis of breast malignancies in individual patients include: size of the primary tumor, stage of the disease at diagnosis, histological grade hormonal, receptor status, and lymph nodes involved with the disease (15, 16) . This retrospective of tumors was of interest because considerable information was available on the majority of the specimens including size of the primary tumor, estrogen receptor status, progesterone receptor status, age of patient, disease stage, HER2/neu, and status of the lymph nodes. Representative sections with tumor and the adjacent normal breast tissue were processed for ER, PR and HER2/neu immunohistochemical staining. For ER and PR staining, sections were taken on histogrip coated slides. Antigen retrieval was done by citrate buffer and the slides were stained with monoclonal antibodies against estrogen and progesterone receptors, 790-4324, anti-ER (SP1) and 790-2223, anti-PR (1E2), (Ventana Inc).
For HER2/neu staining, after antigen retrieval, slides were marked with antibody against HER2/neu oncoprotein, PATHWAY anti-HER2/neu , 790-2991, (Ventana Inc). The slides were counterstained with Mayer hematoxylin. The intensity of HER2/neu overexpression was graded by 0, 1+, 2+, or 3+. Overexpression of HER2/neu was defined as positive 2+, 3+ membranous staining in the invasive carcinoma cells.
Tumor specimens were considered negative for ER and PR if staining for both receptors was negative; specimens were considered positive for ER/PR if staining for both receptors was positive. A scoring system was also used, which was based on the estimated fraction of positively stained cells. Some authors regard any evincible staining (> 0%) as a positive result, (17, 18) whereas some use 10%, (19) or at least 20% nuclei staining as positive results (20) . Therefore, in the current study, we used the percentage of positive malignant cells, and the cutoff points for negative expression were less than 10% of positive nuclear staining.
Statistical Analyses
Continuous variables were described by the median with range, and qualitative variables by the size and percentage rate. We used Freeman-Halton extension of Fisher's test to compute the two-tailed probabilities in contingency tables to examine the categorical variables and to assess possible associations between clinicopathological and molecular factors. The results were considered statistically significant if the p value was ≤ 0.05. All analyses were performed with SPSS version 15 for Windows. 
Features

RESULTS
This study is, to our knowledge, the only comprehensive evaluation of the biological and clinical characteristics of Albanian breast cancers patients that are ER+, PR+ or HER2/neu+ compared with those that are ER−, PR− or HER2/neu−. There were 110 breast cancer patients analyzed during the study period. The frequency of ER, PR patients with age, tumour size, number of nodes involved, histological grade, HER2/neu, and recurrent disease are summarized in Table 2 . The mean patients age was 51 (28-71 years) with SD = 10.74. The overall ER expression was 69% and PR expression 67%. ER− and PR− tumors were more frequent at age > 50 years, while receptors positive were particularly high among women aged less than 50 years.
The majority of the patients, 76% of ER negative tumors and 78% of PR negative expression were in T2 stage. In this respect, only 1,8% of ER negative tumors were in stage T1 compared with 12,7% in ER positive group and 0,9% PR negative tumors presented with T1 stage compared with 13,8 % in PR positive group. However, ER receptor did not show statistically significant association with tumor stage.
Histological grade III was more common in ER, PR negative tumors (24% and 24%, respectively), which was higher in comparison with ER+, PR+ phenotype (9.2% and 8%, respectively). A positive association was seen between histological grade and negative steroid receptors expressions (Table 2) . Amongst 110 patients with breast carcinoma, lymph node metastases were present in 63 cases (57%) with ER expression and 60 cases (55%) with PR expression. Tumors with lymph node metastasis showed no association with ER and PR.
Relapse rate was not affected by estrogen and progesterone receptors expression. Nevertheless, ER− and PR− tumors were more likely than ER+ and PR+ tumors to relapse (18% and 19% vs. 14%, respectively).
Because of patient factors as well as service factors, HER2/ neu over-expression/amplification testing was not being routinely advised. As a result, only in 39 from 110 patients HER2/neu analysis was conducted. Overexpression of HER2/neu was seen in 16 (41%) of our patients. Triple positivity (ER+, PR+,HER2/ neu+) was expressed in only 10% of the patients, compared with 31% of the patients HER2/neu positive and steroid receptors negative. Furthermore, triple negative tumors occurred in 21% of the patients in our study (Table 3 ). In the HER2/neu breast cancer patients was found a statistically significant inverse association of HER2/neu with ER/PR receptors (p = 0.02) (Table3). ER/PR negative tumors were more likely to be HER2/neu positive (75%) than were ER/PR positive tumors. Our findings showed a significant correlation of tumor size (p = 0.003) and nodal status (p = 0.03) with HER2/neu overexpression. The likelihood of having metastatic disease increased in the group of patients with HER2/neu overexpressing protein (69% vs. 35%). Recurrent disease was noted in 6 (15%) patients. No associations were found between relapse and histological grade and HER2/neu tumors.
DISCUSSION
This study focused on the evaluation of relationship between clinicopathological and molecular factors in a poor studied group of Albanian women. Although there is an agreement on the prog- nostic and predictive significance of testing ER expression, the additional benefit from the assessment of PR receptor still remains controversial (5) . In Albania, the significance of hormone receptors and HER2/neu expression and their potential association and prognosis are still largely unknown. Our data showed the significant association of ER receptor expression with histological grade and PR expression with tumor size. In our study, as compared with others (9, 10, 22-24), no correlation was found between ER or PR and lymph node status, suggesting that the hormonal receptors are not predictors of metastatic potential. Among patients with ER− and PR− tumors, recurrence was higher than in ER+, PR+ tumors but association was not significant as seen in previous studies (25) .
ER+
The frequency of hormones receptor-positive breast cancer has been found to be high as in the western countries (65% to 80%) (26, 27) . ER+ and PR+ tumors were more likely to be associated with younger age at diagnosis compared to ER− and PR− tumors. ER−, PR− tumors displayed features of a more aggressive biological phenotype than ER+, PR+ tumors. This evaluation allowed identification of patients with high-risk features for whom new treatments are needed (1, (4) (5) (6) .
HER2/neu levels are closely associated with adverse clinicopathological and molecular factors. In his work, Seshadri et al. (28) studied a group of 1,056 patients with breast cancer diagnosed between 1987 and 1990. After a median follow up of 39 months, he concluded that overexpression of HER2/neu correlated significantly with stages of disease, with lymph nodes and absence of ER, PR receptors. In our study, the elevated values of HER2/neu tissue status in the primary tumors were associated significantly with tumor size, nodal status and decreased hormonal receptors.
We showed that the presence of ER and PR receptors in human breast cancer cell lines resulted in a strong reduction of HER2/neu protein overexpression. HER2/neu overexpression correlated with absence of ER expression (3, 21, (28) (29) (30) (31) which is in line with other studies. The exact molecular mechanism of this phenomenon remains to be elucidated, but the finding of estrogen-mediated down-regulation of HER2/neu in breast cancer cell lines implies the existence of reciprocal control at the level of gene regulation (32) . In our results, 16 (41%) of the breast cancer women had HER2/neu overexpression. In general, 70-90% of all breast cancer patients are considered to be HER2/ neu negative by standard tissue tests (12, 13) . The higher percentage of HER2/neu positive tumors might be attributed to the low number of patients undergoing HER2/neu analysis, which limited the number of subgroups HER2/neu+ and HER2/neu− cases, engendering possible insignificant differences. Considering the importance of evaluating HER2/neu expression, we strongly feel that this issue should be further investigated taking into account patients' management and alternative therapeutic strategies (33) .
The overexpression of HER2/neu reflects the activity of tumor cells and the clinical course of disease towards progression or regression. HER2/neu plays an important role in cell proliferation and differentiation, and its overexpression seems to correlate with an increase in the proliferative activity of breast cancer cells (28, 34) . We also showed that the HER2/neu status was a prognostic indicator and HER2/neu+ patients had higher metastatic potential than HER2/neu− patients (75% vs. 34.7%). Analysis of all breast cancer patients for elevated HER2/neu levels can provide valuable information for patient management in both the HER2/neu positive and HER2/neu negative groups. ER signalling pathways in breast cancer and HER2/neu overexpression are associated with resistance to hormonal therapy which would take in consideration alternative therapeutic strategies as the number of HER2/neu targeted drug choices continues to increase.
CONCLUSION
A combination of ER, PR and HER2/neu and prognostic factors could be of clinical value in defining subgroups in Albanian breast cancer patients that might benefit from more aggressive treatment. 
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